Gregory Adams

Company: Elucida Oncology Inc.

Job title: Chief Scientific Officer

Seminars:

Targeted C’Dot Drug Conjugates (CDCs). An Ultra-Small Delivery Platform That Addresses Limitations of ADCs 1:00 pm

CDCs ultra-small 6-7 nM size facilitates deeper tumor penetration and delivery to difficult to target tumors including those in the brain coupled with rapid systemic elimination which can enhance therapeutic efficacy with decreased off-target toxicities. The unique chemistry of the platform allows for the attachment of up to 80 payload molecules and targeting moieties to…Read more

day: Day Two